Ponatinib is a novel potent, orally available small molecule multitargeted kinase inhibitor. Ponatinib inhibits both native and mutant BCR-ABL. Ponatinib is used in the treatment of chronic myeloid leukemia (CML) with BCR-ABL kinase inhibitors.Melting Point:As reportedSolubility:As reported Method for Determining Identity: Proton NMR (DMSO-d6) Spectroscopic and Mass Spectrometric AnalysisTLC Conditions: As reported Storage and Stability: May be stored at RT for short-term only. Long-term storage is recommended at 4°C. For maximum recovery of product, centrifuge the original vial prior to removing the cap. Light sensitive. Store under inert atmosphere.Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.Toxicity and Hazards: All products should be handled by qualified personnel only, trained in laboratory procedures.
